Diamond-Blackfan Anemia 14 with Mandibulofacial Dysostosis (DBA14) — Research Report

1. Disease Information

Overview. Diamond-Blackfan anemia 14 with mandibulofacial dysostosis (DBA14) is an extremely rare, X-linked form of Diamond-Blackfan anemia (DBA) — a congenital ribosomopathy characterized by pure red cell aplasia — occurring together with a Treacher-Collins/mandibulofacial-dysostosis-like craniofacial malformation spectrum (microtia, absent external auditory canals, micrognathia, cleft palate/midface hypoplasia). It is caused by hemizygous missense mutation of TSR2 (TSR2 ribosome maturation factor), Xp11.22, and has to date been reported in a single kindred (two affected maternal first cousins) (PMID:24942156).

Key identifiers: - OMIM (phenotype): #300946 — DIAMOND-BLACKFAN ANEMIA 14 WITH MANDIBULOFACIAL DYSOSTOSIS; DBA14 - OMIM (gene): 300945 — TSR2 RIBOSOME MATURATION FACTOR; TSR2 - MedGen: C4225422 - MONDO: MONDO:0010493 - Gene: TSR2, HGNC:25455 (aliases: DBA14, WGG1, DT1P1A10), Xp11.22 - Sibling/allelic-spectrum entries:* DBA15 (OMIM #606164, RPS28-caused, autosomal), DBA10 (RPS26), all part of the broader "DBA with mandibulofacial dysostosis" phenotype cluster first delineated by Gripp et al. (PMID:24942156) - DBA14 does not currently carry its own dedicated Orphanet number distinct from the general Diamond-Blackfan anemia entry (Orphanet ORPHA:124); it is catalogued there as a molecular subtype.

Synonyms: DBA with mandibulofacial dysostosis (TSR2-related); Diamond-Blackfan anemia, X-linked, with craniofacial anomalies.

Evidence base: Aggregated disease-level knowledge derived from a single published family report (two affected males, index case followed to age 24, cousin to age 16), supplemented by general Diamond-Blackfan anemia registry data (mostly RPS19/RPL5/RPL11/other-gene DBA) and by biochemical/structural studies of TSR2 protein function done in yeast, human cell, and in vitro biophysical systems — not from an EHR-scale cohort. Nearly everything specific to this entity (as opposed to DBA broadly) traces to one report.

2. Etiology

Disease-causal factor. A single hemizygous missense variant in TSR2: c.191A>G, p.(Glu64Gly) (E64G), located within the conserved "WGG domain" of the 191-amino-acid TSR2 protein. Segregation was consistent with X-linked inheritance — hemizygous in both affected males, heterozygous (carrier) in their mothers, who are sisters (PMID:24942156). In silico pathogenicity: PolyPhen-2 = 1.0 (probably damaging), SIFT = 0 (damaging), GERP = 5.91 (highly conserved position) (PMID:24942156).

Genetic risk factors. The only known causal factor is hemizygosity for this TSR2 missense allele; no other TSR2 variant has yet been reported to cause human disease. By analogy to other DBA genes, this is a haploinsufficiency/dominant-negative-type ribosomal-biogenesis lesion rather than a null allele — a fully null TSR2 allele is presumed embryonic lethal or far more severe, since TSR2 is essential for ribosome maturation (see Mechanism, below).

Modifier/allelic-series context. The craniofacial-plus-DBA phenotype is genetically heterogeneous: the same 2014 report that described the TSR2 family also identified two unrelated de novo RPS28 c.1A>G mutations (translation start-codon loss) causing an overlapping phenotype (subsequently OMIM'd separately as DBA15, #606164), and noted that RPS26 (DBA10) mutations can produce a similar craniofacial-DBA combination (PMID:24942156). This established that "DBA + mandibulofacial dysostosis" is a converging phenotype of at least three distinct small-subunit ribosome-biogenesis genes (TSR2, RPS26, RPS28) rather than a single-locus entity — an important lump/split consideration.

Environmental/lifestyle risk factors. None identified; this is a purely monogenic disorder with no known environmental, infectious, or lifestyle contribution to primary disease causation. (General DBA disease-modifying environmental factors — e.g., infection or drug exposure precipitating aplastic crises in any bone-marrow-failure syndrome — are theoretical extrapolations, not TSR2-specific data.)

Protective factors. None reported specific to TSR2. General DBA literature notes that a minority of patients experience spontaneous or steroid-induced remission, but no protective genetic modifier has been characterized for DBA14 specifically.

Gene-environment interaction. Not established for this entity.

3. Phenotypes

Data below are from the single reported kindred (PMID:24942156) unless otherwise noted; frequencies should be read as "observed in both/one of two reported patients," not population frequencies.

Severity/progression: The craniofacial malformations are static congenital anomalies (Treacher-Collins-like spectrum); the hematologic phenotype is variable within the family — from steroid-responsive transfusion-independent anemia (proband) to purely biochemical DBA markers without anemia (cousin), illustrating marked intrafamilial variable expressivity, a recognized feature of DBA broadly.

Quality-of-life impact: Conductive hearing loss and craniofacial dysmorphism carry the same functional burden documented generally for mandibulofacial dysostosis/Treacher Collins spectrum (speech/hearing-language development impact, psychosocial burden of facial difference); chronic anemia when present carries fatigue/growth burden typical of DBA. No DBA14-specific QoL instrument data exist; extrapolation from general DBA and Treacher Collins QoL literature is reasonable but should be flagged as extrapolated, not measured in this entity.

4. Genetic/Molecular Information

Causal gene: TSR2 (HGNC:25455; OMIM *300945; Xp11.22). Encodes a 191-amino-acid protein containing a conserved "WGG domain" (residues ~11–92) whose specific fold was historically "of unknown function" at the time of the 2014 report but has since been structurally characterized (see Mechanism).

Pathogenic variant: - NM_058233 (representative transcript); c.191A>G, p.Glu64Gly - Variant classification: reported as likely pathogenic/pathogenic on the basis of segregation, absence in controls, and in silico prediction (PolyPhen-2 1.0, SIFT 0, GERP 5.91) (PMID:24942156); functional validation later published (see below). - Variant type: missense, hemizygous (X-linked) - Zygosity/origin: germline, inherited (maternal carriers); not somatic - Population frequency: not reported in gnomAD/ExAC at time of publication; effectively private to this family (no independent confirmatory family has been published as of current literature searches).

Functional consequence — direct experimental confirmation. The E64G substitution was functionally tested in a yeast complementation/humanized system: yeast expressing human TSR2^E64G showed strong growth impairment and defective 20S pre-rRNA processing (cytoplasmic accumulation of the ITS1-containing pre-rRNA reporter), directly demonstrating loss of TSR2's normal ribosome-maturation activity (PMID:24942156; mechanistic follow-up in PMID:30201955). Structural/biophysical work (PMID:30201955) subsequently showed that the DBA-linked TSR2 mutant is specifically impaired in binding the eukaryotic-specific segment (ESS) of ribosomal protein eS26/RPS26 — the molecular interaction TSR2 normally uses to escort RPS26 — directly linking the E64G lesion to the RPS26-chaperone defect (see Mechanism §6).

Modifier genes: None specific to TSR2-DBA14 established. Broader DBA literature documents highly variable expressivity even for the same causal ribosomal-protein gene, attributed to unknown modifiers, but no locus has been mapped for TSR2 specifically.

Epigenetic information: Not reported for DBA14/TSR2. (General ribosomopathy literature discusses secondary transcriptional/translational stress-response reprogramming — e.g., ATF4 pathway dysregulation — rather than primary epigenetic lesions; see Mechanism.)

Chromosomal abnormalities: None reported; this is a single-nucleotide missense lesion, not a structural rearrangement.

5. Environmental Information

No environmental, toxic, occupational, or infectious contributing factors have been identified or are plausible as primary causes, given the clearly monogenic X-linked etiology. No lifestyle risk-factor literature exists specific to this entity. (As with other bone-marrow-failure syndromes, intercurrent infection could theoretically exacerbate cytopenia, but this is inferential, not documented for DBA14.)

6. Mechanism / Pathophysiology

Causal chain (numbered, from lesion to phenotype)

1. Hemizygous TSR2 c.191A>G (p.Glu64Gly) disrupts the WGG-domain surface of the TSR2 escortin/chaperone protein (demonstrated functionally in a yeast complementation assay: PMID:24942156).
2. This leads to impaired binding between TSR2 and the eukaryotic-specific segment (ESS) of ribosomal protein eS26 (RPS26) — the interaction TSR2 normally uses (a) to escort cytoplasmic-imported RPS26 by disassembling the importin–RPS26 complex in a RanGTP-independent, non-canonical mechanism, and (b) to chaperone RPS26 incorporation into, and reversible release from, the nucleolar pre-40S particle (PMID:30201955; general TSR2/RPS26 mechanism reviewed via PMID for the "dual key lock" 40S-maturation step and the Tsr2–Rps26 chaperone-cycle biochemistry, e.g. eLife 2020/61254 and the 2021 Tsr2–Rps26 release/reincorporation study).
3. This results in defective 20S pre-rRNA processing / impaired 40S small-subunit maturation — directly shown as cytoplasmic accumulation of unprocessed pre-rRNA (Cy3-ITS1 reporter) in cells expressing the mutant (PMID:24942156). This step is analogous mechanistically to the RPS26-null and RPS28-null lesions found in the same family report, converging all three genes on the same terminal 40S-maturation checkpoint.
4. Impaired ribosome biogenesis leads to "nucleolar stress" — accumulation of free, unassembled ribosomal proteins that bind and inhibit HDM2 (MDM2), the negative regulator of p53, in the canonical DBA mechanism established for other ribosomal-protein genes (general DBA mechanism literature, e.g. PMID:21930148 and related). This step is inferred by analogy to other DBA genes rather than directly demonstrated for TSR2-E64G specifically — an important evidence-directness caveat.
5. p53 stabilization/activation, together with p53-independent pathways — notably loss of actively translated ATF4, a master regulator of the integrated stress response and of erythroid differentiation, shown across multiple DBA ribosomal-protein deficiencies — leads to cell-cycle arrest and/or apoptosis preferentially in erythroid progenitors, which have unusually high ribosome demand during rapid proliferation/differentiation (general ribosomopathy mechanism; PMC12096137, and PMID:21930148-class reviews). This explains the erythroid-lineage-selective bone-marrow failure (pure red cell aplasia) despite the ubiquitous requirement for ribosomes.
6. In parallel (branch point), defective ribosome biogenesis during embryonic/fetal craniofacial morphogenesis leads to apoptosis of neural-crest-derived cephalic/first- and second-branchial-arch precursor cells — the same convergent mechanism established for TCOF1-, POLR1C/POLR1D-, and other ribosomopathy-driven mandibulofacial dysostosis/Treacher Collins spectrum disorders, where correct "dosage" of ribosome-biogenesis machinery is specifically required for cephalic neural crest cell survival (general Treacher Collins mechanism literature). This branch is inferred by mechanistic analogy — TSR2-specific neural-crest data do not exist — producing the micrognathia, microtia, midface hypoplasia, and downslanting palpebral fissures.
7. The combined erythroid and craniofacial-neural-crest consequences of steps 5 and 6 result in the clinical DBA14 phenotype: congenital macrocytic anemia plus Treacher-Collins-like craniofacial malformation, occurring together because both tissue lineages are simultaneously vulnerable to the same underlying ribosome-biogenesis insult during development.

Molecular pathways

Ribosome biogenesis / 40S small-subunit maturation pathway (pre-rRNA processing, KEGG "Ribosome biogenesis in eukaryotes"); downstream nucleolar-stress → p53 (MDM2/HDM2–p53 axis) and ATF4/integrated-stress-response pathways.

Cellular processes

Impaired ribosomal protein assembly/nuclear import–export cycling (RanGTP-independent importin disassembly); apoptosis and cell-cycle arrest in erythroid progenitors; apoptosis of cranial neural crest cells.

Protein dysfunction

TSR2 acts as a dual-function molecular chaperone ("escortin") for RPS26/eS26: (a) it recognizes the ESS segment of eS26 to trigger non-canonical disassembly of the importin:eS26 nuclear-import complex, and (b) it regulates reversible release and reincorporation of eS26 from mature 40S ribosomes under stress (redox/salt/pH), enabling a ribosome-mediated stress response. The E64G substitution impairs the ESS-binding interface, disabling both functions (PMID:30201955; bioRxiv/PMC8880767-class mechanistic follow-up work on Tsr2–Rps26 release/reincorporation biology).

Tissue damage mechanisms

Selective failure of erythroid progenitor proliferation/survival (bone marrow); developmental (not degenerative) tissue-patterning failure in first/second branchial arch derivatives — mechanistically distinct from oxidative/ischemic damage models used elsewhere in the KB.

Suggested ontology terms

• GO (biological process): GO:0042274 (ribosomal small subunit biogenesis), GO:0000462 (maturation of SSU-rRNA from tricistronic rRNA transcript), GO:0006446 (regulation of translational initiation — secondary), GO:0006974 (DNA damage response — for p53 axis, if used generically for nucleolar stress signaling), GO:0036503 (ERAD pathway — not applicable), GO:0043066 (negative regulation of apoptotic process — for the p53/MDM2 axis, inverted as appropriate)
• GO (molecular function): GO:0043022 (ribosome binding), GO:0008565 (protein transporter activity — for the importin-disassembly role)
• CL (cell types): CL:0000765 (erythroblast) / CL:0000038 (erythroid progenitor cell), CL:0000333 (migratory neural crest cell) / CL:0002321 (embryonic cell, cranial neural crest lineage)

7. Anatomical Structures Affected

Organ level: - Primary: bone marrow (erythroid lineage — pure red cell aplasia); craniofacial skeleton and soft tissue (mandible, maxilla/midface, external and middle ear) - Secondary: reproductive system (unilateral cryptorchidism in the proband) — plausibly a co-occurring neural-crest/genital-ridge developmental association rather than a direct ribosome-biogenesis erythroid mechanism - Body systems: hematologic/immune (bone marrow), craniofacial/musculoskeletal, otologic/auditory, ophthalmologic (periorbital structures), genitourinary

Tissue/cell level: - Erythroid progenitor cells in bone marrow (CL:0000765/CL:0000038) - Cranial neural crest–derived mesenchyme forming first (mandibular) and second (hyoid) branchial/pharyngeal arch structures (CL:0000333) - Middle/external ear structures (first and second arch derivatives)

Subcellular level: - Nucleolus (site of pre-rRNA processing and TSR2/RPS26 pre-40S assembly) — GO:0005730 (nucleolus) - Cytoplasm (site of late 40S maturation and TSR2-mediated RPS26 release/reincorporation cycling) — GO:0005737

Localization (UBERON): UBERON:0002371 (bone marrow), UBERON:0000453 (jaw region)/UBERON:0001676 (mandible), UBERON:0001703 (upper jaw region/midface), UBERON:0001846 (external auditory meatus), UBERON:0001846-adjacent middle ear structures, UBERON:0002190 (subcutaneous adipose — not relevant), UBERON:0000151 (pharyngeal arch)

Lateralization: Craniofacial anomalies were bilateral in both patients (microtia bilateral); cryptorchidism was unilateral in the proband.

8. Temporal Development

Onset: Craniofacial anomalies are present at birth (congenital, developmental origin in embryogenesis — first/second branchial arch patterning occurs in the first trimester). The hematologic phenotype in the reported proband was diagnosed at age 10 months, consistent with the general DBA pattern in which anemia is discovered within the first two years of life; diagnosis after age 4 is rare in classical DBA (general DBA epidemiology). The cousin's laboratory DBA markers (elevated MCV, eADA, HbF) were present without ever developing overt anemia — illustrating that TSR2-DBA14, like DBA generally, can present as a purely biochemical/subclinical hematologic phenotype.

Progression: The hematologic component in the index case was steroid-responsive; no long-term natural-history data (beyond follow-up to age 24) exist to characterize typical disease-course trajectory, remission likelihood, or transfusion dependence risk specific to TSR2-DBA14. Craniofacial anomalies are static structural malformations, not progressive.

Pattern: No relapsing-remitting pattern reported; anemia responded to corticosteroid treatment in the one treated patient and has remained controlled to at least age 24 per the report. No spontaneous-remission data specific to this gene are available.

9. Inheritance and Population

Epidemiology. DBA14 (TSR2-related) has been reported in exactly one family (two affected males) worldwide as of the primary literature search (PMID:24942156); no population-level prevalence/incidence estimate exists for this specific molecular subtype. For context, Diamond-Blackfan anemia overall has an estimated incidence of ~5–7 per 1,000,000 live births (roughly 1/150,000 in some European estimates), with TSR2 accounting for a vanishingly small fraction of the ~50–60% of DBA cases with an identified ribosomal-protein-pathway gene (RPS19 ~25% is the largest single contributor; RPL5, RPL11, RPS10, RPS17, RPS24, RPS26, RPL35A collectively contribute another ~25–35%; RPS28 and TSR2 are each represented by only one to a few families in the literature).

Inheritance pattern: X-linked (segregating as hemizygous-affected males, heterozygous unaffected/biochemically-marked carrier females in the one reported pedigree) (PMID:24942156). Suggested HP term for the mode of inheritance: HP:0001417 (X-linked inheritance); given only affected males and obligate-carrier transmitting females are reported, this reads as X-linked recessive-pattern segregation in the single pedigree, though with only two affected individuals formal recessive-vs-other X-linked distinction cannot be firmly established from this family alone.

Penetrance/expressivity: Marked variable expressivity within the one reported family — the proband had transfusion-requiring, steroid-responsive anemia plus a fuller craniofacial phenotype, while the cousin had only laboratory DBA markers (no anemia) with a somewhat different, still overlapping, craniofacial presentation (cleft palate rather than cryptorchidism, for example). This mirrors the well-documented variable expressivity seen across DBA generally, even for identical causal variants.

Genetic anticipation: Not applicable/not reported (not a repeat-expansion disorder).

Germline mosaicism: Not reported for this family.

Founder effects / consanguinity: Not applicable — the report describes an X-linked pedigree with maternal-cousin transmission, not a founder-population or consanguinity-driven case.

Carrier frequency: Unknown/not established (n=1 family; variant not seen in population databases at publication).

Population demographics: No ethnic, geographic, or sex-ratio data beyond the single reported (presumably North American, given the reporting center) family; as an X-linked disorder, males are hemizygously affected while carrier females may show attenuated/subclinical hematologic markers, consistent with typical X-linked recessive dynamics, though formal female-carrier phenotyping data are limited to the two reported obligate-carrier mothers.

10. Diagnostics

Clinical/laboratory tests: - Complete blood count showing macrocytic, normochromic anemia with reticulocytopenia and normal white cell/platelet counts (classical DBA diagnostic criterion) - Bone marrow examination: normal cellularity with a selective paucity of erythroid precursors (classical DBA criterion) - Erythrocyte adenosine deaminase (eADA) activity: elevated — a well-validated DBA biomarker with ~84% sensitivity, ~95% specificity, and ~91% positive/negative predictive value versus other inherited bone-marrow-failure syndromes (PMID:23252420-class literature); used here to identify the biochemically-affected but non-anemic cousin - Fetal hemoglobin (HbF): elevated — supporting minor diagnostic criterion for DBA - Craniofacial imaging (CT temporal bone for ear/middle-ear anatomy; standard clinical craniofacial exam) to characterize microtia/atresia, micrognathia, midface hypoplasia

Genetic testing: - Given the phenotypic overlap between DBA and mandibulofacial dysostosis/Treacher Collins spectrum, the recommended approach is a combined ribosomal-protein-gene/ribosome-biogenesis-factor panel or exome sequencing including RPS19, RPL5, RPL11, RPS10, RPS17, RPS24, RPS26, RPL35A, RPS7, RPS29, RPL15, RPL26, TSR2, and RPS28, alongside classical mandibulofacial dysostosis genes (TCOF1, POLR1C, POLR1D, EFTUD2) when craniofacial features dominate — reflecting genetic heterogeneity of the combined phenotype (PMID:24942156 explicitly frames this as a diagnostic message: "DBA with mandibulofacial dysostosis is heterogeneous") - Single-gene TSR2 Sanger sequencing is reasonable when family history/segregation suggests X-linked inheritance - Chromosomal microarray/karyotype: not indicated as a primary test (this is a single-nucleotide missense disorder), but useful to exclude alternative structural causes of craniofacial anomaly + cytopenia phenotypes - Carrier/segregation testing recommended for at-risk maternal relatives in an identified family, given the demonstrated carrier (heterozygous, biochemically-detectable-but-non-anemic) phenotype pattern

Differential diagnosis: - Other DBA molecular subtypes with craniofacial features (RPS26/DBA10, RPS28/DBA15) - Treacher Collins syndrome (TCOF1, POLR1C, POLR1D) without hematologic involvement - Mandibulofacial dysostosis, Guion-Almeida type (EFTUD2), which includes microcephaly and esophageal atresia but not classically DBA-type anemia - Other inherited bone marrow failure syndromes (Fanconi anemia, Shwachman-Diamond syndrome) — excluded via eADA pattern, HbF pattern, and absence of the syndrome-specific features (radial ray defects, pancreatic insufficiency, etc.)

Screening: No population or newborn screening program exists for this ultra-rare entity; screening in practice is limited to cascade testing of at-risk relatives once a proband is identified.

11. Outcome/Prognosis

No dedicated survival, mortality, or long-term outcome data exist for TSR2-DBA14 specifically (n=1 family, longest follow-up to age 24). By extrapolation from general DBA outcome data (not TSR2-specific): - General DBA prognosis is favorable for the anemia itself with corticosteroid or transfusion management, but carries substantial treatment-related and disease-related long-term morbidity - General DBA carries a markedly elevated lifetime cancer risk: myelodysplastic syndrome (a "few hundred-fold" increased relative risk in registry data) and acute myeloid leukemia, plus solid tumors — notably early-onset colorectal/gastrointestinal carcinoma and osteosarcoma — with a cumulative malignancy risk approaching 20% by age 40 in DBA Registry data (ASH/Blood registry literature) - No TSR2-specific cancer-predisposition data exist; whether TSR2-DBA14 carries the same elevated malignancy risk as other DBA subtypes is an inferred extrapolation, not directly demonstrated, and should be flagged as such in any curated entry - Craniofacial and hearing outcomes follow the general trajectory for mandibulofacial dysostosis/Treacher-Collins-spectrum disease: static structural anomaly amenable to surgical/audiologic management, with functional hearing loss requiring amplification (hearing aids were used in the reported proband)

12. Treatment

No TSR2-DBA14-specific treatment trial or outcome data exist; management follows general DBA and general mandibulofacial dysostosis/craniofacial-anomaly paradigms.

Pharmacotherapy (hematologic): - Corticosteroids (e.g., prednisone) — first-line for DBA-associated anemia; the reported proband's anemia was explicitly steroid-responsive (PMID:24942156). NCIT term: NCIT:C15986 (Pharmacotherapy) with therapeutic_agent corticosteroid class (NCIT:C2322) - Chronic red blood cell transfusion with iron chelation for steroid-refractory/intolerant cases (general DBA management, not documented as needed in this specific family) - Danazol has been reported as an underutilized adjunct in general DBA management (PMC6636591-class literature) — not documented for this family specifically

Advanced therapeutics: - Allogeneic hematopoietic stem cell transplantation (HSCT) — potentially curative for the hematologic component in steroid-refractory general DBA, though associated with significant transplant-related morbidity/mortality; gene therapy approaches are in early clinical development for DBA broadly but have not been reported for TSR2-DBA14. NCIT: NCIT:C15431 (Hematopoietic Cell Transplantation)

Surgical/interventional (craniofacial): - Standard mandibulofacial dysostosis/craniofacial surgical management: ear reconstruction/atresia repair, orthognathic/mandibular distraction or reconstructive surgery for micrognathia, cleft palate repair (as needed in the cousin) — extrapolated from general Treacher Collins/MFD surgical management, not TSR2-DBA14-specific data. NCIT: NCIT:C15329 (Surgical Procedure), NCIT:C16186 (Orthopedic Surgical Procedure, if applicable to mandibular work)

Supportive/rehabilitative: - Hearing aids for conductive hearing loss (used by the reported proband) — NCIT device-qualifier pattern (NCIT:C15302 Physical Therapy is not applicable; consider audiologic amplification device via qualifiers pattern, since NCIT has no direct "hearing aid usage" clinical-action term) - Speech/language therapy for cleft-palate-associated speech impact (general MFD management, not documented specifically in this family) - Genetic counseling for the family (NCIT:C15240)

Experimental: No registered clinical trials specific to TSR2-DBA14 were identified. General DBA trials (e.g., sotatercept, trifluoperazine — both identified in general DBA trial searches, NCT01464164 and NCT03966053) are not gene-subtype-specific and their applicability to TSR2-mediated disease is untested.

13. Prevention

No primary prevention is possible for this monogenic disorder beyond genetic counseling and reproductive options (carrier testing of at-risk female relatives, prenatal diagnosis, or preimplantation genetic testing once a familial TSR2 variant is identified) — standard for any X-linked Mendelian disorder, not TSR2-DBA14-specific literature. Secondary prevention centers on early recognition of the biochemical DBA phenotype (as demonstrated in the non-anemic cousin, identified via eADA/HbF/MCV screening) in at-risk relatives, enabling monitoring for later-onset anemia and enrollment in cancer surveillance protocols recommended generally for DBA (given the cancer-predisposition profile of DBA broadly). Tertiary prevention follows general DBA cancer-surveillance guidance (colonoscopy and other age-appropriate screening given elevated colorectal cancer and MDS/AML risk in DBA registries), extrapolated rather than demonstrated for this gene.

14. Other Species / Natural Disease

No naturally occurring TSR2-mutant disease has been reported in non-human species (companion animals, livestock, or wildlife); no OMIA entry exists for this gene-disease combination. TSR2 orthologs are broadly conserved across eukaryotes (yeast Tsr2 through human TSR2), reflecting the essential, deeply conserved nature of the ribosome-maturation function itself (see Model Organisms below) rather than any documented spontaneous veterinary phenotype.

15. Model Organisms

Yeast (Saccharomyces cerevisiae) — functional/complementation model: The pathogenicity of the human TSR2 E64G variant was directly demonstrated using a yeast humanized/complementation system: yeast strains expressing human TSR2^E64G in place of endogenous Tsr2 showed strong growth impairment and defective 20S pre-rRNA processing (cytoplasmic ITS1 reporter accumulation), providing direct functional evidence that this variant impairs TSR2's role in ribosome maturation (PMID:24942156). This is a gain of mechanistic insight but not a whole-organism disease model — it establishes molecular loss-of-function, not organismal phenocopy of anemia/craniofacial malformation.

Yeast — structural/biochemical model of the Tsr2–Rps26 chaperone cycle: NMR structural and cross-linking mass-spectrometry work (PMID:30201955) defined the Tsr2–eS26(ESS) binding interface in molecular detail and directly showed the DBA-linked mutant is selectively impaired in this interaction; subsequent biochemical work (2021, e.g. the Tsr2–Rps26 release/reincorporation stress-response study) further elaborated Tsr2's dual role in RPS26 nuclear escort and in reversible RPS26 disassembly from mature 40S ribosomes under oxidative/pH stress. These are molecular/biochemical models (recombinant protein, in vitro reconstitution), not organismal models, and their translational fidelity to human craniofacial and hematopoietic development is inferential.

Mouse: Tsr2 has an annotated mouse ortholog (MGI:1916749), but no published Tsr2-mutant or Tsr2-knockout mouse model recapitulating DBA-like anemia or craniofacial malformation was identified in this search. This is a genuine translational gap — unlike TCOF1 (Treacher Collins) and several other DBA genes (e.g., Rps19, Rpl11 mouse/zebrafish models), no whole-organism model exists to test whether the E64G lesion (or Tsr2 haploinsufficiency generally) reproduces the combined erythroid-failure-plus-craniofacial phenotype in vivo. This should be recorded as a HUMAN_MODEL_MISMATCH/knowledge-gap class finding if curated into dismech: evidence for the mechanism exists at the molecular/biochemical (yeast, in vitro) level, but organismal fidelity to the human phenotype (particularly the craniofacial neural-crest component) is unconfirmed in any animal model.

Zebrafish: No TSR2-specific zebrafish model was identified in this search, in contrast to other ribosomopathy genes (e.g., rps19, rpl11 morphants/mutants used extensively to model DBA hematopoietic phenotypes and to study neural-crest/craniofacial ribosomopathy convergence in zebrafish more generally).

Summary of Key Citations

Explicit evidence-directness note: Beyond the single foundational case report (PMID:24942156) and the follow-up molecular-mechanism paper on the E64G–ESS interaction (PMID:30201955), essentially all mechanistic (nucleolar stress/p53/ATF4), craniofacial-neural-crest, cancer-predisposition, and treatment-outcome content in this report is extrapolated by analogy from the broader Diamond-Blackfan anemia and Treacher Collins/mandibulofacial dysostosis literatures rather than demonstrated specifically for TSR2-DBA14. Any curation into dismech should carry directness: INDIRECT on evidence items sourced from this general-DBA/general-MFD literature rather than from the two TSR2-specific primary papers, and should flag the absence of any animal model as a structural knowledge gap rather than silently assuming mechanistic parity with better-studied DBA genes.

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• GO:0006974 (1 mention) - the report calls it "DNA damage response — for p53 axis, if used generically for nucleolar stress signaling"; GO calls it DNA damage response
• UBERON:0000453 (1 mention) - the report calls it "jaw region"; UBERON calls it decidua basalis
• UBERON:0001676 (1 mention) - the report calls it "mandible"; UBERON calls it occipital bone
• UBERON:0001703 (1 mention) - the report calls it "upper jaw region/midface"; UBERON calls it neurocranium
• UBERON:0000151 (1 mention) - the report calls it "pharyngeal arch"; UBERON calls it pectoral fin

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0008565 (obsolete protein transporter activity) (1 mention)

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• HP:0011903 (1 mention) - the report calls it "Increased hemoglobin F"; HP calls it HbH hemoglobin, and lists "Hemoglobin H" among its other names
• GO:0000462 (1 mention) - the report calls it "maturation of SSU-rRNA from tricistronic rRNA transcript"; GO calls it maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA)
• GO:0006446 (1 mention) - the report calls it "regulation of translational initiation — secondary"; GO calls it regulation of translational initiation
• GO:0036503 (1 mention) - the report calls it "ERAD pathway — not applicable"; GO calls it ERAD pathway
• GO:0043066 (1 mention) - the report calls it "negative regulation of apoptotic process — for the p53/MDM2 axis, inverted as appropriate"; GO calls it negative regulation of apoptotic process
• GO:0008565 (1 mention) - the report calls it "protein transporter activity — for the importin-disassembly role"; GO calls it obsolete protein transporter activity
• CL:0002321 (1 mention) - the report calls it "embryonic cell, cranial neural crest lineage"; CL calls it embryonic cell (metazoa)
• UBERON:0001846 (2 mentions) - the report calls it "external auditory meatus"; UBERON calls it internal ear
• UBERON:0002190 (1 mention) - the report calls it "subcutaneous adipose — not relevant"; UBERON calls it subcutaneous adipose tissue
• NCIT:C16186 (1 mention) - the report calls it "Orthopedic Surgical Procedure, if applicable to mandibular work"; NCIT calls it Orthopedic Surgical Procedure
• NCIT:C15240 (1 mention) - the report calls it "Genetic counseling for the family"; NCIT calls it Genetic Counseling

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA, MGI.